Telix Pharmaceuticals Limited
TLX | NASDAQ
$11.31
-$1.28 (-10.17%)
At close: Sep 21, 2026, 4:00 PM ET
$11.95
+$0.64 (+5.66%)
Pre-market:
Sep 22, 2026, 5:56 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 1.21B | 783.21M | 502.55M | 160.1M | 7.6M | 5.21M |
Cost of Revenue | 565.2M | 273.53M | 188.16M | 65.17M | 38.68M | 2.02M |
Gross Profit | 640.23M | 509.68M | 314.39M | 94.93M | 5.05M | 3.19M |
Operating Income | 26.64M | 82.13M | 15.84M | -91.93M | -81.25M | -44.19M |
Interest Income | 8.74M | 10.86M | 671K | 1K | n/a | 67K |
Pretax Income | -7.9M | 56.06M | 3.09M | -98.62M | -99.04M | -60.25M |
Net Income | -10.69M | 49.92M | 5.21M | -104.08M | -80.51M | -44.89M |
Selling & General & Admin | 356.77M | 207.13M | 134.16M | 87.1M | 46.99M | 19.21M |
Research & Development | 256.82M | 121.03M | 128.84M | 57.86M | 34.14M | 23.09M |
Other Expenses | n/a | 99.39M | 270K | 41.9M | -27.82M | -13.24M |
Operating Expenses | 613.59M | 427.55M | 263.27M | 186.86M | 53.3M | 29.05M |
Interest Expense | 55.06M | 21.46M | 8.94M | 406K | 195.68K | 1.18M |
Selling & Marketing Expenses | 211.77M | 85.47M | 54.87M | 37.97M | 5.89M | 1.2M |
Cost & Expenses | 1.18B | 701.08M | 486.71M | 252.03M | 91.98M | 54.47M |
Income Tax Expense | 2.79M | 6.14M | -2.07M | 5.46M | -18.53M | -15.37M |
Shares Outstanding (Basic) | 337.88M | 331.23M | 319.18M | 310.64M | 282.21M | 257.27M |
Shares Outstanding (Diluted) | 337.88M | 345.19M | 323.71M | 310.64M | 282.21M | 257.27M |
EPS (Basic) | -0.03 | 0.15 | 0.02 | -0.34 | -0.29 | -0.17 |
EPS (Diluted) | -0.03 | 0.14 | 0.02 | -0.34 | -0.29 | -0.17 |
EBITDA | 79.83M | 98.23M | 22.97M | -92.84M | -70.07M | -44.94M |
EBIT | 47.17M | 92.55M | 16.22M | -98.22M | -75.25M | -44.19M |
Depreciation & Amortization | 32.67M | 5.69M | 6.74M | 5.38M | 5.17M | 4.31M |
Add to Watchlist
Select watchlists to add or remove TLX